Company intelligence / Profile preview

Chiasma

Waltham, Massachusetts, United Stateschiasma.co ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Successfully completed Phase 3 clinical trials for octreotide capsules (Mycapssa®) for acromegaly treatment. Mycapssa was launched in the US in August 2020 as the first oral somatostatin analog for long-term maintenance treatment of acromegaly[6][9].

Therapeutic areas: OncologyEndocrinology
Modalities: Oral formulations of injectable therapies
Industry: Biotech

Drug pipeline

2 assets

octreotide

Commercial

Indications: Acromegaly

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chiasma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chiasma.

Explore the full profile